<DOC>
	<DOCNO>NCT00141011</DOCNO>
	<brief_summary>The primary purpose study determine whether brief intravenous infusion ancrod start within 6 hour stroke onset improves functional outcome 3 month .</brief_summary>
	<brief_title>Ancrod ( Viprinexâ„¢ ) Treatment Acute , Ischemic Stroke</brief_title>
	<detailed_description>With prior approval FDA , interim analysis futility perform 500 subject enter two parallel trial , NCT00141001 NCT00300196 . The analysis review data safety monitor board , recommend study terminate futility . This do point 650 subject entered study , combine , analysis conduct initial 500 subject . Results abbreviate analysis find study NCT00141001 since study contribute subject analysis .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Brain Infarction</mesh_term>
	<mesh_term>Ancrod</mesh_term>
	<criteria>Acute , ischemic stroke first symptom within 6 hour begin treatment Baseline NIHSS &gt; 5 No intracranial , extravascular blood CT Hypertension ( systolic &gt; 185 ; diastolic &gt; 105 ) Baseline fibrinogen level &lt; 100 mg/dL Thrombocytopenia ( &lt; 100,000 / mm3 ) Recent ( &lt; 3 day ) anticipate ( &lt; 5 day ) use thrombolytic agent Recent ( &lt; 14 day ) anticipate surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Fibrinogen</keyword>
	<keyword>Reperfusion</keyword>
	<keyword>Thrombolysis</keyword>
</DOC>